雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性分析

Safety analysis of raltitrexed for intraperitoneal chemotherapy in laparoscopic radical resection of colorectal cancer

目的探讨腹腔镜结直肠癌根治术中雷替曲塞用于腹腔灌注化疗的安全性。方法从我院2017年5月~2018年5月选取58例行腹腔镜结直肠癌根治术的结直肠癌患者,将患者随机分成两组,每组29例。对照组采用常规手术方式,观察组采用术中雷替曲塞腹腔灌注化疗的方式。观察比较两组患者的相关毒性指标和不良反应发生情况。结果观察组患者治疗后白细胞计数(WBC)、红细胞计数(RBC)、血肌酐(Cr)、血小板计数(PLT)、尿素氮(BUN)、天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)指标与对照组无显著差异(P>0.05),观察组不良反应发生率为31.03%,相比对照组不良反应发生率为37.93%,两组数据差异无统计学意义(P>0.05)。结论腹腔镜结直肠癌根治术中雷替曲塞用于腹腔灌注化疗,不会增加患者的毒副作用和不良反应,具有较好的安全性。

Objective To investigate the safety of raltitrexed for intraperitoneal chemotherapy in laparoscopic radical resection of colorectal cancer. Methods From May 2017 to May 2018, 58 patients with colorectal cancer who underwent laparoscopic radical resection of colorectal cancer were selected and randomly divided into two groups, with 29 cases in each group. The control group was given conventional surgical approach. The observation group was treated with intraoperative intraperitoneal chemotherapy with raltitrexed. The relevant toxicity indicators and adverse reactions occurred in the two groups were observed and compared. Results There was no significant difference in white blood cell count(WBC), red blood cell count(RBC), serum creatinine(Cr), platelet count(PLT), urea nitrogen(BUN), aspartate aminotransferase(AST), and alanine aminotransferase(ALT) between the observation group and the control group after treatment(P>0.05). The incidence of adverse reactions in the observation group was 31.03%, and the incidence of adverse reactions in the control group was 37.93%. There was no significant difference between the two groups(P>0.05). Conclusion In the laparoscopic radical resection of colorectal cancer, raltitrexed for intraperitoneal chemotherapy does not increase the side effects and adverse reactions of patients, and has good safety.